TGFB1 and urinary bladder cancer: Therefore, the results obtained in this study utilizing TGF-β signaling antagonists provide a rationale for further pre-clinical studies in order to dissect the TGF-β signaling pathway to obtain full benefit from this pathway targeted therapy as a single agent or in combination against bladder cancer as well as other solid tumors dependent upon TGF-β signaling.